Zymeworks announces positive Phase 3 results for Ziihera in first-line HER2+ GEA

Zymeworks Inc.

Ziihera + chemo showed statistically significant PFS improvement vs trastuzumab + chemo; OS trend with further analysis expected mid-2026.
Ziihera + Tevimbra (tislelizumab) + chemo showed statistically significant improvements in both OS and PFS vs control.
PFS and OS benefit observed across PD-L1 positive and negative subgroups in the triple combo arm.
Jazz plans to submit supplemental BLA in 1H-2026; Zymeworks eligible for milestones and royalties.
Safety profile consistent with known safety of each agent; no new signals observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.